World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
80
Citations
40090
World Ranking
16889
National Ranking
64

Overview

Ho Yeong Lim is affiliated with the Samsung Medical Center in South Korea and has contributed extensively to the field of medicine, particularly focusing on oncology and hepatology. Their research portfolio includes numerous publications addressing various cancer treatments, with a strong emphasis on hepatocellular carcinoma and related topics.

The main fields of study for Ho Yeong Lim include:

  • Medicine

Within this broad field, their subfields of expertise are:

  • Oncology
  • Hepatology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Surgery

Ho Yeong Lim's primary research topics cover a range of cancer-related areas, notably:

  • Hepatocellular Carcinoma Treatment and Prognosis
  • Colorectal Cancer Treatments and Studies
  • Cancer Immunotherapy and Biomarkers
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Cancer Genomics and Diagnostics
  • Gastric Cancer Management and Outcomes
  • Pancreatic and Hepatic Oncology Research

The scientist regularly publishes in several medical journals, with frequent contributions appearing in:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Liver Cancer
  • Cancer Research
  • Therapeutic Advances in Medical Oncology

Ho Yeong Lim has collaborated often with several co-authors, including:

  • Jung Yong Hong
  • Masatoshi Kudo
  • Hong Jae Chon
  • Joon Oh Park
  • Richard S. Finn

Some of the recent papers associated with their research include:

  • Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma, 2020, New England Journal of Medicine
  • Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma, 2021, Journal of Hepatology
  • Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours, 2020, British Journal of Cancer
  • Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study, 2021, Journal of Clinical Oncology
  • Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial, 2021, The Lancet Oncology

Best Publications

  • Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

    Richard S Finn;Shukui Qin;Masafumi Ikeda;Peter R Galle

  • Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

    Brian I. Rini;Bernard Escudier;Piotr Tomczak;Andrey Kaprin

  • Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Andrew X Zhu;Yoon-Koo Kang;Chia-Jui Yen;Richard S Finn

  • Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

    Richard S. Finn;Baek-Yeol Ryoo;Philippe Merle;Masatoshi Kudo

  • Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

    Atsushi Ohtsu;Manish A. Shah;Eric Van Cutsem;Sun Young Rha

  • Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

    Seung Tae Kim;Razvan Cristescu;Adam J. Bass;Kyoung Mee Kim

  • Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.

    Thomas Yau;Yoon Koo Kang;Tae You Kim;Anthony B. El-Khoueiry

  • Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

    Jeong Heo;Tony Reid;Leyo Ruo;Caroline J. Breitbach

  • Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone

    Jung Hun Kang;Soon Il Lee;Do Hyoung Lim;Keon Woo Park

  • Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial

    Jeeyun Lee;Do Hoon Lim;Sung Kim;Se Hoon Park

  • Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

    Josep M. Llovet;Thomas Decaens;Jean-Luc Raoul;Eveline Boucher

  • Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours.

    David S. Hong;Yoon Koo Kang;Mitesh Borad;Jasgit Sachdev

  • Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.

    Andrew X. Zhu;Masatoshi Kudo;Eric Assenat;Stéphane Cattan

  • Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study

    Jeeyun Lee;Se Hoon Park;Heung Moon Chang;Jun Suk Kim

  • Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses

    Se Hoon Park;Tae Sung Sohn;Jeeyun Lee;Do Hoon Lim

  • Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma

    Thomas E. Hutson;Bernard Escudier;Emilio Esteban;Georg A. Bjarnason

  • Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma

    Robert J. Motzer;Naomi B. Haas;Frede Donskov;Marine Gross-Goupil

  • Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

    Sandrine Faivre;Eric Raymond;Eveline Boucher;Jean Douillard

  • Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

    Robin Kate Kelley;Bruno Sangro;William Harris;Masafumi Ikeda

  • 2018 Korean Liver Cancer Association-National Cancer Center Korea practice guidelines for the management of hepatocellular carcinoma

    Joong Won Park;June Sung Lee;Kyung Suk Suh;Jin Wook Chung

Frequent Co-Authors

Jeeyun Lee
Jeeyun Lee Sungkyunkwan University
Won Ki Kang
Won Ki Kang Samsung Medical Center
Joon Oh Park
Joon Oh Park Samsung Medical Center
Masatoshi Kudo
Masatoshi Kudo Kindai University
Ann-Lii Cheng
Ann-Lii Cheng National Taiwan University
Andrew X. Zhu
Andrew X. Zhu Harvard University
Yoon-Koo Kang
Yoon-Koo Kang Asan Medical Center
Richard S. Finn
Richard S. Finn University of California, Los Angeles
Josep M. Llovet
Josep M. Llovet University of Barcelona
Jee Woo Park
Jee Woo Park Seoul National University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Medicine doesn’t have to start or end with a traditional M.D. degree. Many healthcare professionals begin with or transition into related nursing roles, often through flexible online programs. If you’re interested in becoming an advanced practice nurse, there are numerous cheapest online nurse practitioner programs available that make this path more financially accessible.

For those looking to elevate their current nursing credentials, earning a master’s in nursing is another strong option. You can find the cheapest online msn programs that combine affordability with comprehensive curriculum.

Nurses interested in leadership, research, or academic roles might consider a doctoral degree. High-quality, affordable phd in nursing programs online can help you reach the highest levels in the field.

Finally, registered nurses seeking to advance can explore cheapest rn to bsn online programs. These online pathways make it easier to balance studies with work and family, while moving up the career ladder in medicine.

Best Scientists Citing Ho Yeong Lim

Trending Scientists